Lisi Group (FII) Q1 2026 TU earnings summary

Executive summary

• Q1 2026 revenue reached €468.0 million, up 10.9% at constant exchange rates and scope, and 5.9% higher year-over-year after the LISI MEDICAL disposal, despite a €24 million adverse currency effect.

• Growth was driven by record aerospace sales, while the automotive segment declined amid global market contraction and lower vehicle production.

Financial highlights

• Q1 2026 revenue: €468.0 million, up 10.9% at constant exchange rates and scope, up 5.9% year-over-year.

• LISI AEROSPACE revenue: €325.1 million, up 17.6% like-for-like (+10.4% reported); LISI AUTOMOTIVE revenue: €143.0 million, down 2.6% like-for-like (-3.5% reported).

• EBIT for 2025 was €98.7 million and net profit €56.0 million, both restated for the medical division sale.

• Adverse currency effect of -€24.0 million (5.1% of revenue), mainly due to a weaker USD/EUR; positive scope effect of +€1.7 million from Hungary integration.

Outlook and guidance

• Aerospace market momentum remains favorable, with strong demand and solid order backlog; capacity expansions prioritized.

• Automotive outlook remains cautious due to low visibility, global market volatility, and geopolitical tensions; operational agility and cost structure adaptation underway.

• Group aims to consolidate leadership in core niches, improve EBIT for a fourth consecutive year, and generate positive Free Cash Flow, assuming stable macro and FX conditions.